1887
Volume 2025, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Papillary thyroid carcinoma (PTC) accounts for 90% of thyroid malignancies, with lymph node metastasis being a critical prognostic factor. However, the mechanisms driving metastasis remain unclear. This study investigated the role of E-cadherin and zinc finger E-box-binding homeobox 1 in cancer progression among Iraqi PTC patients.

The expression levels of E-cadherin and zinc finger E-box-binding homeobox 1 were analyzed in 50 Iraqi patients diagnosed with PTC without lymph node metastases, evaluated between January 2015 and December 2021. The Pearson correlation coefficient between these markers and the risk of lymph node metastasis, as well as their relationship to tumor grade and stage, was calculated. The area under the receiver operating characteristic (ROC) curve for both markers was performed. The Medical Ethics Committee of the Iraqi Ministry of Higher Education and Scientific Research (Reference No. 14) approved the study.

This study examined 50 PTC cases, revealing significant associations between E-cadherin and zinc finger E-box-binding homeobox 1 expression and lymph node metastasis, clinical stage, and tumor grade. Zinc finger E-box-binding homeobox 1 expression was higher in metastatic cases (92% vs. 16%), while E-cadherin was lower (24% vs. 84%). Zinc finger E-box-binding homeobox 1 positively correlated with lymph node metastasis ( = 0.68), stage ( = 0.72), and grade ( = 0.56), whereas E-cadherin showed negative correlations ( = −0.60, −0.59, and −0.52, respectively). ROC analysis showed areas under the curve of 0.88 zinc finger E-box-binding homeobox 1 and 0.82 (E-cadherin), suggesting their potential as biomarkers for metastasis prediction.

The study concluded that E-cadherin and zinc finger E-box-binding homeobox 1 are key predictors of lymph node metastasis, tumor grade, and stage in PTC. Monitoring these markers could enhance clinical decision-making and patient management.

© 2025 Amer, Aldujaily, Alfatlawi, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2025.45
2025-06-30
2025-12-07

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/qmj/2025/2/qmj.2025.45.html?itemId=/content/journals/10.5339/qmj.2025.45&mimeType=html&fmt=ahah

References

  1. Hu S, Wu X, Jiang H. Trends and projections of the global burden of thyroid cancer from 1990 to 2030. J Glob Health. 2024; 14:: 04084. https://doi.org/10.7189/jogh.14.04084
     [Google Scholar]
  2. Abdullah MI, Junit SM, Ng KL, Jayapalan JJ, Karikalan B, Hashim OH. Papillary thyroid cancer. Genetic alterations and molecular biomarker investigations. Int J Med Sci. 2019; 16:(3):450–60. https://doi.org/10.7150/ijms.29935
    [Google Scholar]
  3. Genpeng L, Jianyong L, Jiaying Y, Ke J, Zhihui L, Rixiang G, et al. Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer. Medicine. 2018; 97:(5):e9619. https://doi.org/10.1097/MD.0000000000009619
     [Google Scholar]
  4. Ekpe-Adewuyi E, Lopez-Campistrous A, Tang X, Brindley DN, McMullen TP. Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition. Oncotarget. 2016; 7:(50):83684–700. https://doi.org/10.18632/oncotarget.13299
     [Google Scholar]
  5. Wan G, Zhu J, Gu X, Yang Y, Liu Y, Wang Z, et al. Human schlafen 5 regulates reversible epithelial and mesenchymal transitions in breast cancer by suppression of ZEB1 transcription. Br J Cancer. 2020; 123:(4):633–43. https://doi.org/10.1038/s41416-020-0873-z
     [Google Scholar]
  6. Lopez-Campistrous A, Adewuyi EE, Williams DC, McMullen TPW. Gene expression profile of epithelial-mesenchymal transition mediators in papillary thyroid cancer. Endocrine. 2020; 72:(2):452–61. https://doi.org/10.1007/s12020-020-02466-3
     [Google Scholar]
  7. Khalifa E. β catenin immunohistochemical expression in papillary thyroid cancer versus benign thyroid lesions in a sample of Iraqi patients. Tex J Med Sci. 2022; 6:: 1–8.
    [Google Scholar]
  8. Batistatou A, Charalabopoulos K, Nakanishi Y, Vagianos C, Hirohashi S, Agnantis NJ, et al. Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin. Endocr Pathol. 2008; 19:(3):197–202. https://doi.org/10.1007/s12022-008-9035-1
     [Google Scholar]
  9. Zhang Y, Liu G, Wu S, Jiang F, Xie J, Wang Y. Zinc finger E-box-binding homeobox 1: its clinical significance and functional role in human thyroid cancer. OncoTargets Ther. 2016; 9:: 1303–10. https://doi.org/10.2147/OTT.S96723
     [Google Scholar]
  10. Hsu Y, Liu C, Yang P, Tsai CH, Lee JJ, Cheng SP. Interaction of age at diagnosis with transcriptional profiling in papillary thyroid cancer. World J Surg. 2016; 40:(12):2922–9. https://doi.org/10.1007/s00268-016-3625-8
    [Google Scholar]
  11. Wirries A, Breyer S, Quint K. Protein kinase C inhibitor treatment attenuates hepatic ischemia and reperfusion injury in diabetic rats. Exp Ther Med. 2016; 12:(1):369–75.
    [Google Scholar]
  12. Liu Y, Wang Y, Zhao K, Li D, Chen Z, Jiang, R, et al. Lymph node metastasis in young and middle-aged papillary thyroid carcinoma patients: a SEER-based cohort study. BMC Cancer. 2020; 20:(1):1–12. https://doi.org/10.1186/s12885-020-6675-0
     [Google Scholar]
  13. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, et al. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab. 2012; 97:(6):878–87. https://doi.org/10.1210/jc.2011-2864
     [Google Scholar]
  14. Naito A, Iwase H, Kuzushima T, Nakamura T, Kobayashi S. Clinical significance of E-cadherin expression in thyroid neoplasms. J Surg Oncol. 2001; 76:(3):176–80. https://doi.org/10.1002/jso.1031
     [Google Scholar]
  15. Ivanova K, Ananiev J, Aleksandrova E, Ignatova MM, Gulubova M. Expression of E-cadherin/beta-catenin in epithelial carcinomas of the thyroid gland. J Clin Pathol. 2017; 5:(2):155–9. https://doi.org/10.3889/oamjms.2017.043
     [Google Scholar]
  16. Gao H, Sun X, Wang H, Zheng Y. Long noncoding RNA SNHG22 increases ZEB1 expression via competitive binding with microRNA-429 to promote the malignant development of papillary thyroid cancer. Cell Cycle. 2020; 19:(10):1186–99. https://doi.org/10.1080/15384101.2020.1749466
    [Google Scholar]
  17. Liu Z, Sun B, Qi L, Li H, Gao J, Leng X. Vascular mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition. Cancer Sci. 2012; 103:(4):813–20.
    [Google Scholar]
  18. Brabant G, Hoang-Vu C, Cetin Y, Dralle H, Scheumann G, Mölne J, et al. E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res. 1993; 53:(20):4987–93.
    [Google Scholar]
  19. Kapran Y, Ozbey N, Molvalilar S, Sencer E, Dizdaroğlu F, Ozarmağan S. Immunohistochemical detection of E-cadherin, α- and β-catenins in papillary thyroid carcinoma. J Endocrinol Invest. 2002; 25:(7):578–85.
    [Google Scholar]
  20. Erdem H, Gündogdu C, Sare Ş. Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma. Exp Mol Pathol. 2011; 90:: 312–7.
    [Google Scholar]
  21. Radulović P, Krušlin B. Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC). Pathol Res Pract. 2018; 1:: 246–51. https://doi.org/10.17305/bjbms.2018.2378
     [Google Scholar]
  22. Chen Z, Li S, Huang K, Zhang Q, Wang J, Li X, et al. The nuclear protein expression levels of SNAI1 and ZEB1 are involved in the progression and lymph node metastasis of cervical cancer via the epithelial-mesenchymal transition. Human Pathol. 2013; 44:(10):2097–105. https://doi.org/10.1016/j.humpath.2013.04.001
     [Google Scholar]
  23. Lee H. Expression of miRNAs and ZEB1 and ZEB2 correlates with histopathological grade in papillary urothelial tumors of the urinary bladder. Virchows Archiv. 2014; 464:(2):213–20. https://doi.org/10.1007/s00428-013-1518-x
     [Google Scholar]
  24. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009; 11:(12):1487–95. https://doi.org/10.1038/ncb1998
     [Google Scholar]
  25. Scheumman GF, Hoang-Vu C, Cetin Y, Gimm O, Behrends J, von Wasielewski R, et al. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J Clin Endocrinol Metab. 1995; 80:(7):2168–72. https://doi.org/10.1210/jcem.80.7.7608273
     [Google Scholar]
  26. Walgenbach S, Sternheim E, Bittinger F, Görges R, Andreas J, Junginger T. Prognostic value of E-cadherin in papillary thyroid carcinoma. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizin. 1998; 69:(2):186–90. https://doi.org/10.1007/s001040050394
     [Google Scholar]
/content/journals/10.5339/qmj.2025.45
Loading
Role of epithelial-mesenchymal markers in predicting metastasis of papillary thyroid carcinoma: A retrospective case-control study
Qatar Medical Journal 2025, 45 (2025); https://doi.org/10.5339/qmj.2025.45
/content/journals/10.5339/qmj.2025.45
/content/journals/10.5339/qmj.2025.45
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): E-cadherin, epithelial-mesenchymal transition, lymph node metastases, Papillary thyroid carcinoma and zinc finger E-box-binding homeobox 1

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error